

Minister Sílvia Paneque visits the HIPRA Campus facilities and highlights its role as a driver of territorial development in health

The Minister learned about the projects HIPRA is working on, both in human and animal health, as part of its commitment to strengthening the country's strategic autonomy.

Girona, November 14, 2025 - The Minister for Territory, Housing and Ecological Transition, and spokesperson for the Catalan Government, Sílvia Paneque, visited the new HIPRA Campus facilities in Aiguaviva this Friday. The Minister toured this new biotechnology innovation centre, which HIPRA inaugurated in September and which is consolidating its position as one of Europe's leading hubs for the research, development, production and distribution of vaccines and biotechnology products for global public health.

During her visit to the R&D and Production facilities, the Minister met with members of the management team, who provided a detailed overview of the projects in which HIPRA is involved, such as the European Commission's SPEEDCELL, the VAX4ASF project against African swine fever project and the company's contribution to HERA's EU FAB programme, aimed at strengthening Europe's health autonomy in the face of future pandemics. She was also informed of the latest updates regarding the inclusion of HIPRA's COVID-19 vaccine in the 2025–2026 vaccination campaign, following the announcement by the Spanish Ministry of Health.

Minister Sílvia Paneque emphasised that “HIPRA Campus is great news for Girona and for Catalonia. It represents an example of how innovation and research can generate opportunities in the territory, attract and retain talent, and promote a model of sustainable development rooted in the country. Projects like this reinforce Catalonia's commitment to balanced, knowledge-based growth.”

HIPRA views territorial commitment and equity as key drivers of innovation, talent attraction and the projection of Girona, Catalonia and Spain on the European map of biotechnology and health innovation.

About HIPRA

HIPRA is a biotechnological pharmaceutical company focused on prevention for both animal and human health (One Health), offering a wide range of highly innovative vaccines and advanced diagnostic services. With its claim “**Building immunity for a healthier world,**” HIPRA reaffirms its commitment to providing solutions that enhance global health.

The company has a strong international presence, **with 40 subsidiaries, 3 R&D centers, and 6 production sites** strategically located in Europe (Spain) and America (Brazil). Its extensive international distribution network reaches nearly 100 countries across five continents.

Research and development are at the core of its expertise. HIPRA **invests more than 15% of its annual revenue in R&D** activities focused on applying the latest scientific advances to develop innovative, high-quality vaccines. HIPRA’s portfolio includes vaccines based on a variety of technological platforms, with R&D teams working with a broad range of technologies and biological modalities.

To add value to its vaccination expertise, the company also develops medical devices and traceability services for animal health.